NCT03936426View on ClinicalTrials.gov

Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATE™

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

July 9, 2018

Primary Completion Date

September 19, 2019

Study Completion Date

September 19, 2019

Conditions
Meningioma
Interventions
DRUG

Cu-64 SARTATE and Cu-67 SARTATE

Cu-64 SARTATE diagnostic drug Cu-67 SARTATE therapy drug

Trial Locations (1)

2065

Royal North Shore Hospital, Sydney

Sponsors
All Listed Sponsors
lead

Clarity Pharmaceuticals Ltd

INDUSTRY